MILAGEN, INC.

Milagen, Inc. is a late-stage, pre-commercial diagnostic company striving to revolutionize the healthcare industry with its focus on commercializing easy-to-use, non-invasive, in vitro diagnostic (IVD) products for the prevention, detection, diagnosis, and management of major cancers. Founded in 1997, the company has been dedicated to advancing health care through its innovative approach. Currently, Milagen is in the process of commercializing novel, proprietary antibody-based blood serum assays for the detection of Breast and Colon cancer recurrence in a CLIA setting. Additionally, the company is gearing up for a major clinical study to support an intended use for the early detection of major cancers. Their efforts have garnered significant attention, with the company securing a notable €3.08M Series B investment on 01 June 2003, with Auriga Partners coming on as the investors. Milagen's commitment to addressing unmet clinical needs through cutting-edge diagnostics positions them as a compelling player in the ever-evolving health care industry.